Zoetis (NYSE:ZTS) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners began coverage on shares of Zoetis (NYSE:ZTS) in a note issued to investors on Monday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $215.00 price target on the stock. Leerink Partners’ target price would suggest a potential upside of 22.68% from the company’s previous close.

Several other research analysts have also recently issued reports on the company. JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler lifted their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $220.80.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $175.25 on Monday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm’s 50-day moving average price is $183.83 and its 200-day moving average price is $180.97. Zoetis has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a market cap of $79.07 billion, a PE ratio of 32.94, a PEG ratio of 2.69 and a beta of 0.89.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the company posted $1.36 earnings per share. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, analysts anticipate that Zoetis will post 5.9 EPS for the current year.

Institutional Investors Weigh In On Zoetis

Several large investors have recently bought and sold shares of the business. Mather Group LLC. raised its position in shares of Zoetis by 19.4% during the 2nd quarter. Mather Group LLC. now owns 3,527 shares of the company’s stock valued at $597,000 after buying an additional 573 shares in the last quarter. CVA Family Office LLC raised its position in Zoetis by 13.5% during the second quarter. CVA Family Office LLC now owns 1,191 shares of the company’s stock valued at $206,000 after purchasing an additional 142 shares during the period. NBC Securities Inc. lifted its stake in shares of Zoetis by 32.1% in the 2nd quarter. NBC Securities Inc. now owns 9,797 shares of the company’s stock valued at $1,698,000 after purchasing an additional 2,383 shares during the last quarter. Valeo Financial Advisors LLC boosted its holdings in shares of Zoetis by 4.6% in the 2nd quarter. Valeo Financial Advisors LLC now owns 7,937 shares of the company’s stock worth $1,376,000 after purchasing an additional 348 shares during the period. Finally, Csenge Advisory Group boosted its holdings in shares of Zoetis by 1.3% in the 2nd quarter. Csenge Advisory Group now owns 5,700 shares of the company’s stock worth $988,000 after purchasing an additional 71 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.